Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded by StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Monday.

Other research analysts have also recently issued research reports about the company. Barclays upped their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Wednesday, July 10th. Finally, Jefferies Financial Group upped their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.89.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded up $0.21 during midday trading on Monday, reaching $17.72. The company had a trading volume of 5,322,384 shares, compared to its average volume of 9,915,385. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The stock has a 50 day moving average price of $17.68 and a 200 day moving average price of $16.13. Teva Pharmaceutical Industries has a fifty-two week low of $8.06 and a fifty-two week high of $19.08. The firm has a market capitalization of $20.07 billion, a PE ratio of -43.22, a P/E/G ratio of 1.26 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.03. The business had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. Analysts anticipate that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current year.

Insider Activity

In other news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares of the company’s stock, valued at $777,285. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.55% of the stock is owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently modified their holdings of TEVA. New Covenant Trust Company N.A. bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $28,000. EntryPoint Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $30,000. Beach Investment Counsel Inc. PA acquired a new stake in Teva Pharmaceutical Industries in the second quarter worth $48,000. Byrne Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $52,000. Finally, Industrial Alliance Investment Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.